Lilly's Jaypirca Gains EU CHMP Nod for CLL Across All Lines

What happened

Lilly announced that the EMA's CHMP issued a positive opinion for Jaypirca (pirtobrutinib) for adult CLL across all lines of therapy, including treatment-naïve and regardless of prior BTK inhibitor use. The recommendation is based on Phase 3 BRUIN CLL-313 and CLL-314 trials showing efficacy in both first-line and comparative settings. If granted EU marketing authorization, Jaypirca would become the first non-covalent BTK inhibitor approved across all CLL lines, complementing its existing U.S. approvals. While this expands Lilly's oncology pipeline and may offer modest revenue diversification, CLL is a competitive space with established covalent BTK inhibitors and emerging alternatives. The core investment thesis remains tethered to tirzepatide and Foundayo performance, as obesity/diabetes accounted for 65% of Q1 revenue; Jaypirca's contribution is unlikely to materially move the earnings needle near-term.

Implication

The CHMP nod de-risks Jaypirca's EU launch and adds a new revenue stream in CLL, but the drug faces entrenched competitors (ibrutinib, acalabrutinib) and pricing pressure. With LLY trading at 39x P/E, the market is pricing obesity leadership, not oncology pickups. Investors should view this as incremental pipeline validation rather than a catalyst for re-rating. Focus remains on Medicare Bridge launch and Foundayo prescription acceleration as the real value drivers over the next 6 months.

Thesis delta

No material shift. The WAIT rating remains appropriate as the core obesity thesis—volume outrunning net price—still needs confirmation. Jaypirca news does not alter the high-conviction call, which hinges on access execution and oral GLP-1 uptake. However, the positive opinion modestly reduces pipeline risk and could support a floor if obesity fundamentals weaken.